Personalis, Inc.
PSNL
Rank in Stocks
#6451
Personalis, Inc. operates globally as a specialized cancer genomics firm. The... Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Share Price
$15.95
Last synced: 2026-11-09
Market Cap
$1.73B
Change (1 day)
1.01%
Change (1 year)
88.98%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Personalis, Inc. (PSNL)
Category
Healthcare
EPS for Personalis, Inc. (PSNL)
EPS as of September 2026 TTM: $-1.17
According to Personalis, Inc.'s latest financial reports, its current EPS (TTM) is $-1.17. At the end of 2025 the company had an EPS of $-0.91, an increase over its 2024 EPS of $-1.37.
EPS history for Personalis, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.17 | 28.57% |
| 2025 | $-0.91 | -33.58% |
| 2024 | $-1.37 | -39.11% |
| 2023 | $-2.25 | -9.27% |
| 2022 | $-2.48 | 66.44% |
| 2021 | $-1.49 | 24.17% |
| 2020 | $-1.20 | -13.67% |
| 2019 | $-1.39 | 52.75% |
| 2018 | $-0.91 | -15.74% |
| 2017 | $-1.08 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $18.99 | -1,723.08% |
US
|
|
| $6.12 | -623.08% |
US
|
|
| $1.38 | -217.70% |
CN
|
|
| $14.83 | -1,367.52% |
US
|
|
| $5.09 | -535.04% |
US
|
Questions about Personalis, Inc.'s earnings per share (EPS)
What is Personalis, Inc.'s earnings per share (EPS)?
Personalis, Inc.'s earnings per share (EPS) over the last twelve months is $-1.17, as of Sep 2026.
What was Personalis, Inc.'s earnings per share (EPS) in 2025?
In 2025, Personalis, Inc.'s earnings per share (EPS) was $-0.91, compared with $-1.37 in 2024.
How has Personalis, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Personalis, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.91) and lowest in 2022 ($-2.48).
How does Personalis, Inc.'s earnings per share (EPS) compare with similar companies?
Personalis, Inc.'s earnings per share (EPS) ($-1.17) is lower than that of all 5 similar companies listed above. The highest among them is Thermo Fisher Scientific Inc., with $18.99.